HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Playtex Realignment Expected To Yield Savings Of $22 Mil.-$24 Mil.

This article was originally published in The Rose Sheet

Executive Summary

Playtex expects to generate cost savings of $12 mil.-$14 mil. in 2005 from a business realignment, with fully annualized savings of $22 mil.-$24 mil. to be realized in 2006, the company reported Feb. 8. The cash generated from the realignment will be used to reinvest in brands and pay down debt

You may also be interested in...



Banana Boat Brand Building Planned Under Playtex Realignment

Playtex plans to strengthen its Banana Boat sun care franchise by launching innovative products and new advertising initiatives, as well as improving relationships with retailers, President and CEO Neil DeFeo reported during an April 5 investor meeting outlining the company's realignment plan

Banana Boat Brand Building Planned Under Playtex Realignment

Playtex plans to strengthen its Banana Boat sun care franchise by launching innovative products and new advertising initiatives, as well as improving relationships with retailers, President and CEO Neil DeFeo reported during an April 5 investor meeting outlining the company's realignment plan

Playtex CEO DeFeo Aims To Accelerate Leading Brand Growth

Playtex' new President and CEO Neil DeFeo said his initial plans for establishing consistent sales and earnings growth at the consumer products firm call for accelerating leading brand growth through innovation and increased marketing

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel